NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis; Aarhus, Denmark, 10 March 2026 – NMD Ph ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results